Pfizer Inc. (NYSE:PFE) Shares Sold by Sovereign Financial Group Inc.

Sovereign Financial Group Inc. lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 16,342 shares of the biopharmaceutical company’s stock after selling 1,233 shares during the period. Sovereign Financial Group Inc.’s holdings in Pfizer were worth $434,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. 626 Financial LLC grew its stake in Pfizer by 15.4% during the 4th quarter. 626 Financial LLC now owns 48,849 shares of the biopharmaceutical company’s stock valued at $1,296,000 after purchasing an additional 6,514 shares in the last quarter. Mayfair Advisory Group LLC lifted its holdings in Pfizer by 4.7% during the 4th quarter. Mayfair Advisory Group LLC now owns 10,758 shares of the biopharmaceutical company’s stock worth $285,000 after buying an additional 479 shares during the last quarter. Ignite Planners LLC lifted its holdings in Pfizer by 11.2% during the 4th quarter. Ignite Planners LLC now owns 37,978 shares of the biopharmaceutical company’s stock worth $1,010,000 after buying an additional 3,834 shares during the last quarter. Wallace Advisory Group LLC lifted its holdings in Pfizer by 4.0% during the 4th quarter. Wallace Advisory Group LLC now owns 16,128 shares of the biopharmaceutical company’s stock worth $467,000 after buying an additional 616 shares during the last quarter. Finally, 180 Wealth Advisors LLC lifted its holdings in Pfizer by 15.4% during the 4th quarter. 180 Wealth Advisors LLC now owns 36,014 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 4,805 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.6 %

Shares of PFE stock opened at $26.25 on Thursday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock has a market cap of $148.76 billion, a PE ratio of 35.47, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The business’s fifty day moving average is $26.13 and its 200-day moving average is $28.03. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm earned ($0.17) EPS. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.55%. Pfizer’s dividend payout ratio (DPR) is 232.43%.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Insider Activity

In related news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.